To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: FDA Grants Priority Review To Vioxx For Osteoarthritis And Pain URL: http://www.pslgroup.com/dg/DAF92.htm Doctor's Guide January 11, 1999
WEST POINT, PA -- Jan. 11, 1999 -- The United States Food and Drug Administration has assigned a six-month priority review to Merck & Co., Inc.'s new drug application for Vioxx(TM) (rofecoxib), an investigational COX-2 specific inhibitor for osteoarthritis and pain. Merck submitted the application for Vioxx on Nov. 23, 1998. The application for Vioxx includes results from 68 studies involving nearly 10,000 patients. Those studies evaluated the safety and efficacy of the once-daily, anti-inflammatory medicine for the treatment of the signs and symptoms of osteoarthritis and for the relief of pain. COX-2 specific inhibitors are being studied to determine whether the apparent differences in how they work may result in fewer certain serious gastrointestinal side effects than nonsteroidal anti-inflammatory drugs, which are medications that are currently available for the treatment of osteoarthritis and pain. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.